Pharmacy Benefit Managers, or PBMs, play an influential role in the prescription drug supply chain, affecting pricing structures, patient access, and reimbursement practices. Increased legislative attention has focused on transparency, oversight, and the broader implications for patients and innovation.
PBM practices directly influence patient access to prescription medicines, reimbursement structures, and overall system costs. In California, policy decisions related to PBM oversight and transparency can affect how therapies reach patients, the sustainability of provider networks, and the state’s ability to support continued biomedical innovation.
Engagement with policymakers and stakeholders focuses on sharing data, market insights, and real-world perspectives to inform balanced, workable policy approaches. This includes policy briefings, legislative meetings, roundtables, and issue education efforts designed to support informed decision-making.
| Bill | Name | CLS Position | Status |
|---|---|---|---|
| AB 2639 2026-27 | PBM Transparency This is what the bill does. Author: Asm. Ben O'Brien | Support CLS letter (PDF) | Introduced Next: Senate Health Hearing, Apr 15 |
Policy Briefs and Letters
Latest Updates